Processing

Please wait...

Settings

Settings

Goto Application

1. WO1995033835 - NUCLEIC ACID IMMUNIZATION USING A VIRUS-BASED INFECTION/TRANSFECTION SYSTEM

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

CLAIMS

1. A method of nucleic acid immunization which results in a cell-mediated immunological response to a selected antigen, said method comprising:
immunizing a vertebrate subject by
(a) introducing a source of bacteriophage T7 RNA polymerase into a cell of said subject; and
(b) transfecting said cell with a recombinant vector comprising a coding sequence which encodes said selected antigen operably linked to the bacteriophage T7 promoter, wherein said transfecting is done under
conditions whereby said coding sequence is transcribed and translated in said cell in the presence of said T7 RNA polymerase,
thereby resulting in the production of a cell-mediated immunological response to said antigen in said vertebrate subject.

2. The method of claim 1 wherein said T7 RNA polymerase is introduced into said cell using a viral vector which expresses a gene encoding said T7 RNA polymerase.

3. The method of claim 2 wherein said viral vector is derived from a poxvirus.

4. The method of claim 3 wherein said
poxvirus is vaccinia virus.

5. The method of claim 3 wherein said
poxvirus is an avipoxvirus.

6. The method of claim 1 wherein said selected antigen is a viral antigen.

7. The method of claim 6 wherein said viral antigen is a human immunodeficiency virus (HIV) envelope glycoprotein.

8. The method of claim 7 wherein said HIV envelope glycoprotein is gpl20.

9. The method of claim 6 wherein said viral antigen is a hepatitis C virus (HCV) envelope
glycoprotein.

10. The method of claim 9 wherein said HCV envelope glycoprotein is E2.

11. The method of claim 1 wherein said recombinant vector is encapsulated in a liposome
preparation.

12. The method of claim 1 wherein said infecting is done prior to said transfecting.

13. The method of claim 1 wherein said
infecting is done subsequent to said transfecting.

14. The method of claim 1 wherein said infecting is done concurrent with said transfecting.

15. The method of claim 1 wherein said T7 RNA polymerase is introduced into said cell using a vector which expresses a gene encoding said T7 RNA polymerase under the control of a T7 RNA polymerase promoter.

16. A method of nucleic acid immunization which results in a cell-mediated immunological response to a selected antigen, said method comprising:
immunizing a vertebrate subject by
(a) infecting a cell of said subject with a vaccinia viral vector that expresses bacteriophage T7 RNA polymerase, to generate an infected cell;
(b) transfecting said infected cell with a liposome-encapsulated recombinant vector comprising a coding sequence which encodes said selected viral antigen operably linked to the bacteriophage T7 promoter, wherein said transfecting is done under conditions whereby said coding sequence is transcribed and translated in said cell,
thereby resulting in the production of a cell-mediated immunological response in said vertebrate subject to said selected viral antigen.

17. The method of claim 16 wherein said viral antigen is a human immunodeficiency virus (HIV) envelope glycoprotein.

18. The method of claim 17 wherein said HIV envelope glycoprotein is gpl20.

19. The method of claim 16 wherein said viral antigen is a hepatitis C virus (HCV) envelope
glycoprotein.

20. The method of claim 19 wherein said HCV envelope glycoprotein is E2.

21. A vaccine composition comprising a recombinant vector which includes a coding sequence for a selected antigen operably linked to the bacteriophage T7 promoter, in admixture with a pharmaceutically acceptable excipient.

22. The vaccine composition of claim 21 wherein said selected antigen is a viral antigen.

23. The vaccine composition of claim 22 wherein said viral antigen is a human immunodeficiency virus (HIV) envelope glycoprotein.

24. The vaccine composition of claim 22 wherein said HIV envelope glycoprotein is gpl20.

25. The vaccine composition of claim 24 wherein said viral antigen is a hepatitis C virus (HCV) envelope glycoprotein.

26. The vaccine composition of claim 25 wherein said HCV envelope glycoprotein is E2.

27. The vaccine composition of claim 21 wherein said recombinant vector is encapsulated in a liposome preparation.

28. A method of making a vaccine composition comprising admixing a recombinant vector which includes a coding sequence for a selected antigen operably linked to the bacteriophage T7 promoter, with a pharmaceutically acceptable excipient.